150 related articles for article (PubMed ID: 35140198)
1. ACE2-Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants.
Ou J; Zhang Y; Wang Y; Zhang Z; Wei H; Yu J; Wang Q; Wang G; Zhang B; Wang C
Signal Transduct Target Ther; 2022 Feb; 7(1):43. PubMed ID: 35140198
[No Abstract] [Full Text] [Related]
2. Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding.
Lin S; Chen Z; Zhang X; Wen A; Yuan X; Yu C; Yang J; He B; Cao Y; Lu G
Signal Transduct Target Ther; 2022 Feb; 7(1):56. PubMed ID: 35190526
[No Abstract] [Full Text] [Related]
3. Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.
Azad T; Singaravelu R; Taha Z; Jamieson TR; Boulton S; Crupi MJF; Martin NT; Fekete EEF; Poutou J; Ghahremani M; Pelin A; Nouri K; Rezaei R; Marshall CB; Enomoto M; Arulanandam R; Alluqmani N; Samson R; Gingras AC; Cameron DW; Greer PA; Ilkow CS; Diallo JS; Bell JC
Mol Ther; 2021 Jun; 29(6):1984-2000. PubMed ID: 33578036
[TBL] [Abstract][Full Text] [Related]
4. A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants.
Duan X; Shi R; Liu P; Huang Q; Wang F; Chen X; Feng H; Huang W; Xiao J; Yan J
Signal Transduct Target Ther; 2022 Jan; 7(1):23. PubMed ID: 35078968
[No Abstract] [Full Text] [Related]
5. Review of studies of severe acute respiratory syndrome related coronavirus-2 pathogenesis in human organoid models.
Egilmezer E; Rawlinson WD
Rev Med Virol; 2021 Nov; 31(6):e2227. PubMed ID: 33763936
[TBL] [Abstract][Full Text] [Related]
6. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
[TBL] [Abstract][Full Text] [Related]
7. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route.
Pan T; Chen R; He X; Yuan Y; Deng X; Li R; Yan H; Yan S; Liu J; Zhang Y; Zhang X; Yu F; Zhou M; Ke C; Ma X; Zhang H
Signal Transduct Target Ther; 2021 Dec; 6(1):420. PubMed ID: 34907154
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development.
Suganya S; Divya S; Parani M
Rev Med Virol; 2021 May; 31(3):e2174. PubMed ID: 32965078
[TBL] [Abstract][Full Text] [Related]
10. Omicron: a drug developer's perspective.
Fang FF; Shi PY
Emerg Microbes Infect; 2022 Dec; 11(1):208-211. PubMed ID: 34951568
[TBL] [Abstract][Full Text] [Related]
11. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
[TBL] [Abstract][Full Text] [Related]
12. The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression.
Pivniouk V; Pivniouk O; DeVries A; Uhrlaub JL; Michael A; Pivniouk D; VanLinden SR; Conway MY; Hahn S; Malone SP; Ezeh P; Churko JM; Anderson D; Kraft M; Nikolich-Zugich J; Vercelli D
J Allergy Clin Immunol; 2022 Mar; 149(3):923-933.e6. PubMed ID: 34902435
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
14. The role of microRNAs in modulating SARS-CoV-2 infection in human cells: a systematic review.
Marchi R; Sugita B; Centa A; Fonseca AS; Bortoletto S; Fiorentin K; Ferreira S; Cavalli LR
Infect Genet Evol; 2021 Jul; 91():104832. PubMed ID: 33812037
[TBL] [Abstract][Full Text] [Related]
15. Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.
Janaka SK; Clark NM; Evans DT; Mou H; Farzan M; Connor JP
PLoS One; 2021; 16(7):e0253551. PubMed ID: 34310603
[TBL] [Abstract][Full Text] [Related]
16. Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment.
Malladi SK; Singh R; Pandey S; Gayathri S; Kanjo K; Ahmed S; Khan MS; Kalita P; Girish N; Upadhyaya A; Reddy P; Pramanick I; Bhasin M; Mani S; Bhattacharyya S; Joseph J; Thankamani K; Raj VS; Dutta S; Singh R; Nadig G; Varadarajan R
J Biol Chem; 2021; 296():100025. PubMed ID: 33154165
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers as an entry for SARS-CoV-2 infection?
Xia P; Dubrovska A
FEBS J; 2020 Sep; 287(17):3677-3680. PubMed ID: 32738184
[TBL] [Abstract][Full Text] [Related]
18. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
19. Evaluating angiotensin-converting enzyme 2-mediated SARS-CoV-2 entry across species.
Zhang HL; Li YM; Sun J; Zhang YY; Wang TY; Sun MX; Wang MH; Yang YL; Hu XL; Tang YD; Zhao J; Cai X
J Biol Chem; 2021; 296():100435. PubMed ID: 33610551
[TBL] [Abstract][Full Text] [Related]
20. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
